Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3424298 | Virology | 2012 | 6 Pages |
With the exception of nucleoside analogs, few direct acting antivirals in clinical development are active across the six major hepatitis C virus genotypes. We report novel consensus sequence chimeras for genotypes 2b, 3a, 4a, 5a, and 6a NS5B and show variable susceptibilities over a panel of NS5B inhibitors. Tegobuvir (GS-9190) had EC50s of <16 nM against genotype 1 and >100 nM for other genotypes tested here. An NS5B F445C mutation engineered into the GT3a, 4a, and 6a chimeric replicons lowered the tegobuvir EC50 to levels comparable to those for genotype 1a, but did not considerably alter the EC50 of site 2 or nucleoside analog inhibitors. These data support the use of HCV chimeras in profiling direct acting antivirals across genotypes and specifically determines the impact of the C445F NS5B polymorphism on tegobuvir potency against genotypes 3a, 4a, and 6a.
► Novel consensus derived NS5B chimeric replicons from GT2b, 3a, 4a, 5a, and 6a. ► Susceptibility of NS5B chimeras to panel of non-nucleoside inhibitors. ► NS5B F445 polymorphism from GT3a, 4a, 6a reduce susceptibility to tegobuvir.